REGN Income Statement
Regeneron Pharmaceuticals Inc - Revenue, Expenses & Profit Analysis
Stock Price
$0.00
Market Cap
-
Most Recent Quarter
Period: 2024-12-31(2024-12-31)
Revenue
Total sales from operations
$14.20B
+8.3% YoY
Net Income
Bottom line profit
$4.41B
Earnings Per Share (Diluted)
Net income per share
$38.34
Profitability Metrics
Historical Income Statements
| Period | Revenue | Gross Profit | Operating Income | Net Income | EPS |
|---|---|---|---|---|---|
| 2024-12-31 | $14.20B | - | - | $4.41B | $38.34 |
| 2023-12-31 | $13.12B | - | - | $3.95B | $34.77 |
| 2022-12-31 | $12.17B | - | - | $4.34B | $38.22 |
| 2021-12-31 | $16.07B | - | - | $8.08B | $71.97 |
| 2020-12-31 | $2.42B | - | - | $1.15B | $10.24 |
View Complete Financial Analysis
Full income statements, balance sheets, cash flows, and AI-powered insights
Open Full AnalysisFrequently Asked Questions
What is REGN's revenue?
REGN's most recent quarterly revenue was $14.20B, representing a growth of 8.3% year-over-year.
Is REGN profitable?
REGN reported a profit of $4.41B in the most recent quarter.
What is REGN's operating income?
Operating income data is available in the income statement.
What is REGN's earnings per share (EPS)?
REGN reported diluted earnings per share of $38.34 in the most recent quarter.
What is REGN's gross profit margin?
Gross margin data is available in the profitability metrics section.